Gulf Pharmaceutical Industries

JULPHAR.AEPhase 1

1000-5000 employeesjulphar.net

Gulf Pharmaceutical Industries, known as Julphar, is a publicly listed company on the Abu Dhabi Securities Exchange (ADX) with a mission to provide high-quality, affordable medicines to the MENA region and beyond. The company has established itself through a diversified portfolio spanning diabetes, cardiovascular, gastroenterology, and anti-infective therapeutic areas. Its strategic direction includes expanding its biosimilars pipeline and leveraging its extensive manufacturing and distribution network for regional growth.

Market Cap

$330M

Pipeline

drug candidates

Patents

—

Publications

—

AI Company Overview

DiabetesCardiovascularGastroenterologyAnti-infectivesPain ManagementOTC & Nutritionals

Technology Platform

Advanced pharmaceutical manufacturing and formulation technologies for complex generics and biosimilars, with in-house biopharmaceutical development capabilities.

Pipeline

3 drugs in pipeline

Drug	Indication	Stage
Julphar Insulin R (soluble human insulin, biosimilar) + Humi...	Diabetes Mellitus	Phase 1
Julphar Insulin N (human isophane insulin) + Huminsulin® Bas...	Diabetes Mellitus	Phase 1
human biphasic insulin + human biphasic insulin, reference	Diabetes Mellitus	Phase 1

Opportunities

Significant growth is available through the expansion of its biosimilars portfolio into new therapeutic areas like oncology, leveraging the large and growing MEA market for affordable biologics.

Further opportunities exist in deepening market penetration in existing geographies and potentially expanding into new emerging markets in Asia and Africa.

Risk Factors

Key risks include intense price competition in the generics sector, execution risks associated with complex biosimilar development and regulatory approval, and exposure to geopolitical and economic instability across its core operating regions in the Middle East and Africa.

Competitive Landscape

Julphar faces competition from regional pharmaceutical firms like Hikma and SPIMACO, as well as global generics and biosimilar players. Its differentiation is rooted in its regional manufacturing footprint, established distribution network, and strategic focus on building in-house biopharmaceutical capabilities for long-term growth.